Study #2020-0133
A Phase 1b Open-label Study to Investigate theSafety and Pharmacokinetics of Administration ofSubcutaneous Blinatumomab for the Treatment ofadults with Relapsed or Refractory B cell PrecursorAcute Lymphoblastic Leukemia (R/R B-ALL)
MD Anderson Study Status
Enrolling
Treatment Agent
Blinatumomab
Description
The study aims to evaluate the safety and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL) and to determine the maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) of SC administered blinatumomab.
Information and next steps
Disease:
B Cell Precursor Acute Lymphoblastic Leukemia
Study phase:
I
Physician name:
Elias Jabbour
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.